Primary Biliary Cirrhosis News and Research RSS Feed - Primary Biliary Cirrhosis News and Research

Primary biliary cirrhosis is a chronic disease that causes the bile ducts in the liver to become inflamed and damaged and, ultimately, disappear. Bile is a liquid produced in the liver that travels through the bile ducts to the gallbladder and then the small intestine, where it helps digest fats and fat-soluble vitamins A, D, E, and K. When the bile ducts become damaged from chronic inflammation, bile builds up in the liver, injuring liver tissue.
State highlights: Rural telemedicine; two Iowa planned parenthoods closed

State highlights: Rural telemedicine; two Iowa planned parenthoods closed

A selection of health policy stories from South Dakota, Washington state, Iowa, Arizona and Georgia. Fifty years in farming had given Tom Soukup a few brushes with his own mortality, but after a cow pinned him against a wall, death felt closer than ever. [More]
Obeticholic acid meets primary composite endpoint in Phase III study

Obeticholic acid meets primary composite endpoint in Phase III study

Results from an international Phase III study presented today at the International Liver CongressTM 2014 have shown obeticholic acid (OCA) given to patients suffering from Primary Biliary Cirrhosis (PBC) who previously had an inadequate response to, or have been unable to tolerate ursodeoxycholic acid (UDCA), produced meaningful biochemical and clinical improvements. UDCA is the only therapy currently approved to treat PBC. [More]
Soligenix initiates orBec Phase 2 study for GI manifestations of chronic GVHD

Soligenix initiates orBec Phase 2 study for GI manifestations of chronic GVHD

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that it has initiated a Phase 2, randomized, double-blind, placebo-controlled study evaluating orBec (oral beclomethasone 17,21-dipropionate or BDP) as a treatment for the gastrointestinal manifestations of chronic Graft-versus-Host disease. [More]
Lumena Pharmaceuticals initiates LUM001 clinical program in children with ALGS

Lumena Pharmaceuticals initiates LUM001 clinical program in children with ALGS

Lumena Pharmaceuticals, a company developing oral therapeutics for rare liver diseases, today announced the initiation of a global clinical program to evaluate its drug candidate LUM001 in children with Alagille syndrome. The first patient has been dosed in the IMAGO Phase II study being conducted in the U.K., and enrollment of pediatric patients is expected to begin later this year in the ITCH Phase II study in the U.S. [More]
Intercept Pharmaceuticals reports financial results for Second quarter 2013

Intercept Pharmaceuticals reports financial results for Second quarter 2013

Intercept Pharmaceuticals, Inc. (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver diseases, such as primary biliary cirrhosis, today reported financial results for the quarter and six months ended June 30, 2013 and announced presentations at an upcoming medical conference and upcoming investor conferences. [More]
Par Pharmaceutical receives final ANDA approval for generic version of Trilipix

Par Pharmaceutical receives final ANDA approval for generic version of Trilipix

Par Pharmaceutical Companies, Inc. today announced that it has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for fenofibric acid EQ 45 mg and EQ 135 mg delayed-release capsules. [More]
Researchers link coffee consumption with reduced risk of primary sclerosing cholangitis

Researchers link coffee consumption with reduced risk of primary sclerosing cholangitis

Research presented today at Digestive Disease Week explores new discoveries in liver disease research, with findings about the impact of coffee on autoimmune disease and palliative care for cirrhotic patients. [More]
Early PBC prognosis advocated

Early PBC prognosis advocated

Biochemical response to ursodeoxycholic acid at 6 months is a better predictor for primary biliary cirrhosis prognosis than the current standard of 1 year, study results suggest. [More]
FDA grants Albireo's A4250 orphan-drug designation for treatment of PFIC and PBC

FDA grants Albireo's A4250 orphan-drug designation for treatment of PFIC and PBC

Albireo AB, a biopharmaceutical company specializing in gastroenterology, today announced that A4250 (an inhibitor of the ileal bile acid transporter, IBAT/ASBT) has been granted orphan-drug designation by the U.S Food and Drug Administration for the treatment of Progressive Familial Intrahepatic Cholestasis (PFIC) and Primary Biliary Cirrhosis (PBC). [More]
Researchers identify three genetic regions associated with primary biliary cirrhosis

Researchers identify three genetic regions associated with primary biliary cirrhosis

Researchers have newly identified three genetic regions associated with primary biliary cirrhosis (PBC), the most common autoimmune liver disease, increasing the number of known regions associated with the disorder to 25. [More]
NCI awards Soligenix $300,000 SBIR grant for orBec Phase 2 chronic GI GVHD trial

NCI awards Soligenix $300,000 SBIR grant for orBec Phase 2 chronic GI GVHD trial

Soligenix, Inc., a development stage biopharmaceutical company, announced today that the National Cancer Institute has awarded Soligenix a Small Business Innovation Research grant to support the conduct of a Phase 2 clinical trial designed to evaluate orBec (oral beclomethasone 17,21-dipropionate or BDP) as a treatment for the gastrointestinal manifestation of chronic Graft-versus-Host disease. [More]
EMA COMP issues positive opinion to Albireo for A4250

EMA COMP issues positive opinion to Albireo for A4250

Albireo AB, a biopharmaceutical company specializing in gastroenterology, today announced that the European Medicines Agency Committee for Orphan Medicinal Products (COMP) has issued a positive opinion on an application for orphan medicinal product status for the company's lead hepatology candidate, A4250. [More]
Rituximab shows promise against primary biliary cirrhosis

Rituximab shows promise against primary biliary cirrhosis

An open-label study of rituximab, a monoclonal antibody for human CD20, was shown to be safe in patients with primary biliary cirrhosis (PBC) who had an incomplete response to the standard ursodeoxycholic acid (UDCA) therapy, also known as Ursodiol. [More]
Liver transplantations for NASH-Cirrhosis increase dramatically

Liver transplantations for NASH-Cirrhosis increase dramatically

Nonalcoholic steatohepatitis (NASH) occurs when fat builds up in the liver. This accumulation of fat damages the liver and leads to cirrhosis. NASH is rapidly increasing in the U.S. mainly related to the epidemics of obesity and diabetes. [More]
Phenex commences Px-102 first-in-man Phase I study for Metabolic Syndrome and NAFLD

Phenex commences Px-102 first-in-man Phase I study for Metabolic Syndrome and NAFLD

Phenex Pharmaceuticals AG announced today the start of a first-in-man Phase I study with its clinical drug candidate Px-102, a synthetic non-steroidal FXR agonist. The volunteers of the first dose level received the drug and showed no signs of discomfort or other adverse effects. [More]
Apollo completes 100 liver transplantations in less than 4 years with over 90% success rate

Apollo completes 100 liver transplantations in less than 4 years with over 90% success rate

Apollo centre for liver disease and transplantation has completed 100 liver transplantations in less than 4 years with over 90% success rate, creating a milestone in the history of medicine. [More]

Obeticholic Acid safe and effective against Primary Biliary Cirrhosis

Results from an international study presented today at the International Liver Congress have shown Obeticholic Acid (OCA) is a safe and effective treatment in patients suffering from Primary Biliary Cirrhosis (PBC) as demonstrated by substantial decreases in the levels of alkaline phosphatase (AP) enzyme in the blood, a key marker for PBC. [More]
Positive results from Intercept OCA Phase II trial in patients with PBC

Positive results from Intercept OCA Phase II trial in patients with PBC

Intercept Pharmaceuticals, Inc., today announced positive results from a 59 patient, placebo controlled, double-blind Phase II clinical trial of obeticholic acid given as monotherapy to patients with primary biliary cirrhosis. [More]
DSP, Intercept enter license agreement for OCA

DSP, Intercept enter license agreement for OCA

Dainippon Sumitomo Pharma Co, Ltd. and Intercept Pharmaceuticals, Inc. today announced that they have entered into an exclusive licensing agreement for the development and commercialization of Intercept's first-in-class FXR agonist obeticholic acid. [More]
Intercept initiates OCA FLINT trial in patients with nonalcoholic steatohepatitis

Intercept initiates OCA FLINT trial in patients with nonalcoholic steatohepatitis

Intercept Pharmaceuticals, Inc., has been informed by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health that patient enrollment has started in a new clinical trial in patients with nonalcoholic steatohepatitis, which will evaluate Intercept's first-in-class farnesoid X receptor agonist obeticholic acid as a novel therapy for NASH. [More]